Question special

Good morning. I agree with our chief resident Dr. Gurgel. The results are promising in patents with refractory hypercholesterolemia including those were therapy has been maximized. This is common in our patient population.

Regarding adverse effects: In the subcutaneous group vs placebo urinary tract infection (11% vs. 8%) was more frequently reported. Through which mechanism or what factors can this finding be attributed? and if so, could this be a potential concern for patients at high risk for sepsis such as the elderly or immunocompromised?